((自动化翻译由路透提供，请见免责声明 )) (更新)
9月24日 - ** 基因治疗生产商蓝鸟生物 股价上涨9.2%至53美分
** 表示 (link)，作为优化现金流重组的一部分，该公司将裁员约25%，目标是在2025年下半年实现收支平衡。
** 到明年第三季度，重组将使运营现金支出减少 20% - Co
** BLUE 表示，由于重组，公司将产生总计 370 万美元的费用，将在截至 12 月 31 日的财年内支付。
** 截至 6 月 30 日，公司共有 375 名全职员工
** 包括本交易日的走势在内，该股今年累计下跌 61.6
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.